Daclizumab (trade name Zinbryta) is a therapeutic humanized monoclonal antibody which was used for the treatment of adults with relapsing forms of multiple sclerosis (MS). Daclizumab …

达利珠单抗（daclizumab）是由渤健（Biogen）和艾伯维（AbbVie）合作开发的一款人源化、可选择性高亲和结合T细胞表面 白细胞介素2 （IL-2）受体亚基CD25的单抗药物。

2016年5月27日 · ZINBRYTA是一种白介素-2受体阻断抗体适用为有多发性硬化症 (MS)的复发型成年患者的治疗。 因为其安全性图形，ZINBRYTA的使用一般地应保留为对两种或更多适用为 …

The primary objective of the study is to evaluate the effects of treatment with daclizumab on the proportion of participants relapse-free at 6 months in Relapsing-Remitting Multiple Sclerosis …

Daclizumab (DAC) is a humanized, monoclonal antibody that blocks CD25, a critical element of the high-affinity interleukin-2 receptor (IL-2R). DAC HYP blockade of CD25 inhibits effector T …

Daclizumab is a humanized monoclonal antibody directed towards CD25, the alpha subunit of the high-affinity interleukin (IL)-2 receptor. Daclizumab exerts its effects via multiple mechanisms, …

2005年6月13日 · Daclizumab is a monoclonal anti-CD25 antibody that blocks the interleukin-2 receptor which is used to treat relapsing forms of multiple sclerosis. Humanized IgG1 Mab that …

The U.S. Food and Drug Administration today approved Zinbryta (daclizumab) for the treatment of adults with relapsing forms of multiple sclerosis (MS). Zinbryta is a long-acting injection that...

达利珠单抗是一种用于治疗多发性硬化症（MS）的生物制剂，其作用机制和使用方法对于患者及其家属至关重要。 本文将详细介绍达利珠单抗的相关信息，帮助读者更好地理解这一治疗选 …

2024年4月19日 · Easy-to-read patient leaflet for Daclizumab. Includes indications, proper use, special instructions, precautions, and possible side effects. Skip to main content